Yuh-Geng Tsay, PHD
Vivo Capital | Venture Partner
Dr. Tsay joined Vivo Capital in 2016 as a Venture Partner. He has extensive experience and track record in building successful businesses that were eventually acquired or went public. Prior to his retirement in 2010 from Thermo Fisher Scientific (NYSE: TMO), Dr. Tsay served as Senior Vice President and Group President of the company’s Specialty Diagnostic business, with worldwide annual revenue of US $2 billion. He was the Group President of Immunodiagnostics of Fisher Scientific (NYSE: FSH) prior to Fisher’s merger with Thermo Electron in 2006. From 2000 to 2004 he served as Group President of Clinical Diagnostics of Apogent (NYSE: AOT), which was acquired by Fisher in 2004. While working for these public companies, he was instrumental in engineering the acquisition of multiple diagnostics companies including Phadia, One Lambda, BRAHMS, Microgenics, Seradyne, Duke Scientifics and Applied Biotech Inc. He was the founder of Diagnostics Reagents Inc., which was acquired by Apogent in 1998. He also cofounded several other diagnostic companies, which were either acquired by a public company or went public.
Dr. Tsay serves on the boards of several biotech companies including PEG Bioscience, PharmaLegacy, AltheaDx, ReadCoor and Bonraybio. He also serves as a Scientific Advisor for Personal Genomics.
Dr. Tsay received his B.S. in Chemistry from the National Cheng Kung University in Taiwan. He has a Ph.D. degree in Organic Chemistry from the University of Rochester, New York. He received a Distinguished Scholar Award from the University of Rochester (2014) and the Distinguished Alumni Awards from Cheng Kung University (2012).